^
    Back
    Association details:
    Biomarker:NUP62 rs9523A>G
    Cancer:Non Small Cell Lung Cancer
    Drug Class:EGFR inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Dovepress
    Title:

    Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients

    Published date:
    10/01/2021
    Excerpt:
    NUP62 rs9523A>G were significantly associated with worse response to EGFR-TKIs, overall survival (OS), and progression-free survival (PFS)….Genetic variants in miRNA binding sites, especially NUP62 rs9523A>G, may be useful in predicting the clinical outcomes of EGFR-mutant lung adenocarcinoma patients treated with EGFR-TKIs.
    DOI:
    https://doi.org/10.2147/PGPM.S329055